What Questcor Investors Absolutely Must Watch


When investing in biotech stocks, investors have to be aware of the numerous risks involved. While binary events such as clinical trial data releases or FDA approval decisions are the most notable, even companies with approved and commercialized drugs can carry serious risks and exposures.

One example of this is Questcor Pharmaceuticals. Sales of its top drug, Acthar, are growing at incredible rates, but the stock's valuation has dropped considerably. In the following video, Brenton Flynn runs through the situation and highlights the key areas investors need to watch with this stock.

If you want more insight on Questcor, we highlight the high-profile issues facing the company inside our brand new premium research report. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

The article What Questcor Investors Absolutely Must Watch originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.